Page 125 - MemoriaEHD-Eng

www.ciberehd.org

• r-g M, p r, a J, s r, g-s J, D M, C J, C-
Most relevant oMeroóMezLaNasMpuerooLàarCíaaMaNiegoiagorespoa
LLeJa JL, turNes J.. Meta-analysis: pegylated interferon α-2a achieves higher early vi-
scientific rological responses than α-2b in chronic hepatitis C.Aliment Pharmacol Ther. 2013;.

articles
• roMero-góMez M, BereNguer M, MoLiNa e, CaLLeJa JL.. Management of anemia induced
by triple therapy in patients with chronic hepatitis C: challenges, opportunities and

recommendations.J Hepatol. 2013;.

• roMero-góMez M, DeL CaMpo Ja.. Insulin resistance, telaprevir, and virological response
in hepatitis C: the debate must go on.Hepatology. 2013;.

• B D, B D, B p, B M, C a, F g, K h, L D, N i,
urgeraCKuggisChutiraxíosterLiNKerarreyiKitiN
poL s, puoti M, roMero-góMez M, WeDeMeyer h, zeuzeM s.. Clinical management of drug-
drug interactions in HCV therapy: challenges and solutions.J Hepatol. 2013;.

• W h, J D, h r J, F p, M MM, z s, r-t M,
eDeMeyereNseNerriNgrereNCiaeuzeMoDríguezorres
BzoWeJ N, poCKros p, vierLiNg J, ipe D, MuNsoN ML, CheN yC, NaJera i, thoMMes J; PRO-
PEL Investigators.. PROPEL: a randomized trial of mericitabine plus peginterferon

alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.Hepato-

logy. 2013;.

The group ended last year FLIP project, funded by the EU FP7, which has succee-
Highlights
ded in developing a non-invasive tool for the diagnosis of liver fibrosis based on

MRI image processing. Several collaborations with other CIBERehd groups has
allowed the publication of results in high-impact journals, emphasizing the mana-

gement of anemia in patients with triple therapy (J.Hepatol) and the analysis of

the interaction of HCV with lipid metabolism.

13
20
T
OR
P
RE
L
A
NU
N
A
D /
H
E
ER
IB
C

125